Overview: Mumps Antibodies Panel
Introduction: The Mumps Antibodies Panel is a diagnostic tool designed to screen for mumps immunity using serum samples. In India, mumps outbreaks occur sporadically (~few thousand cases/year reported, higher in unvaccinated clusters), with complications (orchitis, meningitis, deafness) more common in adolescents/adults due to incomplete MMR coverage in rural/low-SES areas. High morbidity from under-testing in outbreak contacts, healthcare workers, or pre-pregnancy screening, limited serology labs, delayed revaccination or immunoglobulin leading to transmission or severe sequelae. Per microbiology practices aligned with ICMR and National Measles-Rubella Elimination Programme guidelines, the test employs immunoassay for mumps IgG (immunity) and IgM (acute infection) over 1-2 days with high accuracy, valuable for confirming seroprotection or recent exposure. This diagnostic falls under immunity screening and targets unvaccinated individuals, outbreak contacts, or those with parotitis, addressing accurate detection to guide MMR vaccination or post-exposure prophylaxis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise immunity verification and reducing mumps complications. Its serum-based approach ensures reliable antibody detection.
Other Names: Mumps Ab Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: IgG/IgM serology standard; in India, used in outbreak surveillance.
Purpose: The test assesses 2 parameters including mumps IgG to guide immunity screening, detect acute/past infection, inform vaccination.
Test Parameters: 1. Mumps IgG, 2. Mumps IgM.
Pretest Condition: No fasting required; patients should have exposure or vaccination history.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on vaccination, parotitis, contact.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected non-immunity including orchitis, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or recent vaccination can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive IgG indicates immunity; IgM positive acute infection, necessitating specialist input.
Specialist Consultation: Infectious disease specialists or pediatricians should be consulted for management.
Additional Supporting Tests: PCR, viral culture for confirmation.
Test Limitations: IgM may persist; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, Vaccine Studies India 2023.
